男友太凶猛1v1高h,大地资源在线资源免费观看 ,人妻少妇精品视频二区,极度sm残忍bdsm变态

Global EditionASIA 中文雙語Fran?ais
Business
Home / Business / Companies

EdiGene completes Series B financing round

By Liu Zhihua | chinadaily.com.cn | Updated: 2020-10-14 14:24
Share
Share - WeChat
A screenshot from EdiGene's official website. [Photo/edigene.com]

The Beijing-based EdiGene Inc, which develops genome editing technologies to accelerate drug discovery and develop novel therapeutics for a broad range of diseases, announced on Tuesday the successful completion of a 450 million yuan ($67 million) round of Series B financing.

Founded in 2015, EdiGene has established four gene editing based platforms and is advancing its early stage programs into clinical development for patients with genetic diseases and cancer.

The four platforms are ex vivo genome editing platforms for hematopoietic stem cells and T cells, in vivo therapeutic platform based on RNA base editing and high-throughput genome-editing screening to discover novel targeted therapies.

In addition, EdiGene has launched a Good Manufacturing Practice facility in 2018 in Guangdong province.

3H Health Investment led the round, and other new investors included Sequoia Capital China, Alwin Capital and Kunlun Capital, along with continued support by previous investors, including IDG Capital, Lilly Asia Venture, Huagai Capital and Green Pine Capital Partners.

Proceeds from the financing will be used to advance the company’s pipeline into clinics and expand the team, the company said.

Wang Minchuan, partner of 3H Health Investment, said as one of the most disruptive biomedical technologies, gene editing is rapidly moving toward clinics globally, and EdiGene is leading the wave in China.

Wang said his firm looks forward to contributing its clinical, business and policy resources to further strengthen the company’s capabilities, and is confident EdiGene is well-positioned to be a leader in gene editing therapeutics.

Wei Dong, CEO of EdiGene, said the financing enables the company to further scale up and transform its pipeline into the clinical stage.

Wei Wensheng, scientific founder of EdiGene, said together with the investors, the company looks forward to translating cutting-edge gene editing technologies into innovative therapies, bringing hope and health to patients and their families.

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
CLOSE
 
主站蜘蛛池模板: 丽水市| 格尔木市| 双峰县| 大厂| 牡丹江市| 蒲江县| 漳平市| 正蓝旗| 河间市| 新沂市| 咸宁市| 蓬溪县| 福贡县| 吴忠市| 筠连县| 綦江县| 惠东县| 望城县| 新安县| 临朐县| 临邑县| 漳州市| 洞头县| 东宁县| 安泽县| 杂多县| 云南省| 中江县| 舞钢市| 西乌珠穆沁旗| 海淀区| 阿合奇县| 太保市| 正安县| 许昌市| 潞城市| 盈江县| 铜川市| 阳谷县| 盐池县| 万安县|